Menstrual Migraine Clinical Trial
— FROVAOfficial title:
Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)
Verified date | April 2018 |
Source | Mclean Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.
Status | Terminated |
Enrollment | 24 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female - Regular Menstrual Phase - Menstrual Migraine - No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.) - No significant medication history, except for migraine - All patients will be currently taking or have previously taken triptan medications for migraine - Weight, <285 pounds - Not claustrophobic - No contraindication to taking triptans Exclusion Criteria: - Age <18 - Significant medical problems (aside from pain before, during and after migraine episodes) - Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.) - Positive alcohol screen - Women taking oral contraceptives - Claustrophobia - History of dermatological hypersensitivity in the facial area - Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit - Pregnancy - Sensory loss detected on Quantitative Sensory Testing at screening - Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week) - Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.) - Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning) - Cardiac pacemakers - Aneurysm clips and other vascular stents, filters, clips or other devices - Prosthetic heart valves - Other prostheses - Neuro-stimulator devices - Implanted infusion pumps - Cochlear (ear) implants - Ocular (eye) implants or known metal fragments in eyes - Exposure to shrapnel or metal filings (sheet metal workers, welders, and others) - Other metallic surgical hardware in vital areas - Use of any of the following medications: - Propanolol/ Inderol - SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox - SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor - triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert - ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert - ketoconazole (Nizoral, Fungoral) - itraconazole (Sporanox) - ritonavir (Norvir) - erythromycin (Erythrocin) |
Country | Name | City | State |
---|---|---|---|
United States | Neuroimaging Center, McLean Hospital | Belmont | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Mclean Hospital | Endo Pharmaceuticals |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04600388 -
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
|
||
Not yet recruiting |
NCT03702114 -
Detecting Auricular Points in MMG by a Novel APD ( APD-MMG )
|
||
Not yet recruiting |
NCT02592681 -
Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine
|
N/A | |
Completed |
NCT01329562 -
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
|
Phase 4 | |
Recruiting |
NCT06173661 -
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
|
Phase 4 | |
Recruiting |
NCT03152305 -
Intracranial Pressure During Migraine
|
N/A | |
Completed |
NCT01578941 -
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine
|
Phase 4 | |
Completed |
NCT04102995 -
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
|
Phase 2 | |
Terminated |
NCT01395264 -
Saccadometry in Primary Headache Syndromes
|
N/A |